Advances in medical treatment for pancreatic neuroendocrine neoplasms

doi:10.3748/wjg.v28.i20.2163

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 20

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5246)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

331

WORD

HTML

2916

Figures (1-2)

338

Tables (1-2)

301

Sum=3950

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

193

Download

395

Sum=588

Publishing Process of This Article

Item

Count

Browse

238

Download

470

Sum=708

May 28, 2022 (publication date) through May 5, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. May 28, 2022; 28(20): 2163-2175
Published online May 28, 2022. doi: 10.3748/wjg.v28.i20.2163

Table 1 Ongoing clinical trials of immune checkpoint inhibitors in combination with other therapies for the treatment of neuroendocrine neoplasms

Drugs	Population	n	Phase	Primary outcomes	NCT number
Surufatinib + toripalimab vs FOLFIRI	NEC	194	III	OS	NCT05015621
Penpulimab + anlotinib	NET	150	II	ORR	NCT04207463
Pembrolizumab + liver-directed/PRRT	NET	32		ORR	NCT03457948
Nivolumab + chemotherapy	NEN G3	38	II	OS	NCT03980925
Toripalimab + FOLFSIM vs EP/EC	Advanced NEC	336	II/III	OS	NCT03992911
Nivolumab + ipilimumab + cabozantinib	PD-NET	30	II	ORR	NCT04079712
Pembrolizumab + lanreotide depot	GEP-NET	22	Ib/II	ORR	NCT03043664

FOLFIRI: Folinic acid, fluorouracil and irinotecan regimen; FOLFSIM: Simmtecan and 5-FU/LV regimen; EP: Etoposide and cisplatin regimen; EC: Etoposide and carboplatin regimen; PD-NET: Poorly differentiated neuroendocrine tumor; ORR: Objective response rate; OS: Overall survival.

Table 2 Ongoing clinical trials of new targeted agents

Drugs	Targets	Population	n	Phase	Primary outcomes	NCT number
Ribociclib + Everolimus	CDK4/6 Inhibitor	Advanced NET	21	II	PFS	NCT03070301
Abemaciclib	CDK4/6 Inhibitor	Advanced GEP-NET	37	II	ORR	NCT03891784
BAY 1895344	ATR Kinase Inhibitor	SCLC/PD-NEC/PDA	87	I	MTD, AEs	NCT04514497
Lurbinectedin, berzosertib	ATR Kinase Inhibitor	SCLC/HGNEC	75	I/II	MTD, ORR	NCT04802174
BI 764532	DLL3 Inhibitor	SCLC/NEN Expressing DLL3	110	I	MTD	NCT04429087
Entinostat	HDAC Inhibitor	Abdominal NET	40	II	ORR	NCT03211988
Niraparib + dostarlimab	PARP Inhibitor	SCLC/HGNEC	48		PFS, ORR	NCT04701307

SCLC: Small-cell lung carcinoma; PD-NEC: Poorly differentiated neuroendocrine carcinoma; PDA: Pancreatic adenocarcinoma; HGNEC: High-grade neuroendocrine cancer; CDK: Cyclin-dependent kinase; ATR kinase: Ataxia telangiectasia and RAD3-related kinase; DLL3: Delta-like protein 3; HDAC: Histone deacetylase; PARP: Poly (ADP-ribose) polymerase; PFS: Progression-free survival; MTD: Maximum tolerated dose; ORR: Objective response rate; AEs: Adverse events.

Citation: Li YL, Cheng ZX, Yu FH, Tian C, Tan HY. Advances in medical treatment for pancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(20): 2163-2175
URL: https://www.wjgnet.com/1007-9327/full/v28/i20/2163.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i20.2163